2 Biopharma Stocks to Add to Your TFSA Today

Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and HLS Therapeutics Inc. (TSX:HLS) offer the potential for huge growth over the next decade.

| More on:
Value for money

Image source: Getty Images

An August report from Grand View Research projected that the global biotechnology market would be worth $727 billion by 2025. Biotherapeutics have emerged as the fastest-growing sector in the pharmaceutical industry. Today we are going to look at two stocks in this sector that are worth your attention.


Zymeworks is a Vancouver-based clinical-stage biopharmaceutical company. It is focused primarily on cancer therapeutics and its leading product candidate, ZW25, is a bispecific antibody which is currently being evaluated in phase 1 trials. Shares of Zymeworks have climbed 49% year over year.

In early January I’d recommended Zymeworks as the perfect growth stock to stash in a TFSA with a long time horizon. The market research firm Mordor Intelligence released a 2018 report that put the cancer therapeutics market value at $136 billion last year. It estimates the market to be worth $220 billion by 2024, which represents a compound annual growth rate (CAGR) of 8.3%.

Zymeworks is set to release its fourth-quarter and full-year results for 2018 next week. In December the company submitted an investigational new drug (IND) application for ZW49, a biparatropic HER2-targeted ADC. January brought more excitement as Zymeworks reported a second IND in collaboration with Eli Lilly Company.

This second IND was on an Azymetric bispecific drug candidate. Both demonstrate that Zymeworks’ platform technologies are yielding consistent success.

The early data for ZW25 is very promising, and if it makes it to market its potential is enormous. Zymeworks stock currently boasts an RSI of 35, putting it just outside of oversold territory ahead of its Q4 earnings release. This stock has home run potential for growth investors.

HLS Therapeutics (TSX:HLS)

HLS Therapeutics is a Toronto-based specialty pharmaceutical company. Shares of HLS Therapeutics were up 8.2% in 2019 as of early afternoon trading on March 5. The stock has soared over 550% over the past year.

The company is expected to release its fourth-quarter results in late March or early April. HLS Therapeutics stock announced its graduation to the Toronto Stock Exchange (TSX) in early February. In the third quarter of 2018 the company established a quarterly dividend policy and declared a payment of $0.05 per share. This currently represents a modest 0.6% yield.

HLS Therapeutics announced a net loss of $19.7 million or $0.72 per share primarily due to one-time costs related to its debt refinancing. Most of HLS`s business is tied to Clozaril, a drug used to treat schizophrenia patients who are not responding to other forms of treatment.

In Q3 2018 the company won FDA rights to distribute Vascepa, a drug which has been shown to reduce cardiovascular events by 25% and death by 20%. It plans to commercialize the drug in Canada this year. HLS estimates that the drug could be worth up to $250 million in sales at peak value in Canada alone.

The stock is a solid value in comparison to the broader TSX index which has grown pricey in recent weeks. HLS is trading at the high-end of its 52-week range, but its potential for massive growth down the line should not be ignored.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned.

More on Investing

stock research, analyze data
Dividend Stocks

How Much to Invest to Get $500 in Dividends Every Month

TSX dividend stocks such as Enbridge, TD Bank, and Telus, can help you earn $500 in monthly dividend payments.

Read more »

A solar cell panel generates power in a country mountain landscape.
Energy Stocks

Clean Energy Play: Is Brookfield Renewable a Good Stock for a TFSA?

Add this top renewable energy stock to your self-directed TFSA portfolio for significant long-term and tax-free wealth growth.

Read more »

Golden crown on a red velvet background
Dividend Stocks

Dividend Powerhouses: Canadian Stocks to Fuel Your Portfolio

These two top Canadian dividend aristocrats are some of the top stocks on the TSX to buy now and hold…

Read more »

Dial moving from 4G to 5G
Dividend Stocks

This Undervalued Dividend Stock is Worth Buying Right Now

Want an undervalued dividend stock with long-term potential and a juicy yield? Here's an option you may regret not buying…

Read more »

A worker gives a business presentation.
Dividend Stocks

1 Stock I’m Buying Hand Over Fist in July Despite the Market’s Pessimism

This top dividend stock is going through a rough patch, but don't let that count out all the growth we've…

Read more »

financial freedom sign

2 Stocks With Millionaire-Maker Potential

These two top Canadian stocks are among the best on the TSX, and each has the potential to be millionaire-maker…

Read more »

Piggy bank next to a financial report
Stocks for Beginners

Is It Finally the Right Time to Buy Bank Stocks?

Canadian bank stocks are some of the most secure investments out there, but of them all, this bank stock is…

Read more »

clock time

3 Blue-Chip Stocks Every Canadian Should Own

Want some reliable blue-chip Canadian stocks to buy and hold for the next 10 years? These three stocks are worth…

Read more »